Cytodyn Inc (CYDY)

[Maverick0408]

Dr. Bruce Patterson has done a lot of work and published in this area. His work shows that there is 100 fold increase in CCL5/Rantes with severe COVID patients. CCL5 is a chemotactic molecule that can amplify inflammatory responses toward immunopathology. Disrupting the CCL5–CCR5 axis via the leronlimab-mediated CCR5 blockade prevent pulmonary trafficking of pro-inflammatory leukocytes and dampen pathogenic immune activation in COVID-19.

Due to its selectivity and target-specific mechanism of action, leronlimab appears to allow chemokine binding (CCL3, CCL4) at therapeutic doses and appears not to be an agonist of the CCR5 receptor (i.e., it does not appear to activate the immune function of the receptor). This apparent target specificity differentiates leronlimab from other CCR5 antagonists. Other potential advantages of leronlimab include longer half-life and less frequent dosing requirements. Plus it’s subcutaneous and therefore can be administered remotely.